Immuneering Corp

Immuneering Corp is a bioinformatics company that is revolutionizing drug discovery and developing transformative medicines. They are dedicated to helping others maximize their data and making a positive impact in the healthcare industry. Their lead clinical stage candidate, IMM-1-104, aims to effectively target tumors driven by mutations in RAS and beyond.

By utilizing deep cyclic inhibition of the MAPK pathway, IMM-1-104 selectively impacts cancer cells to a greater extent than healthy cells. This innovative approach shows promising potential for universal-RAS activity. In addition to IMM-1-104, Immuneering Corp has a robust pipeline of novel drug programs, including IMM-6-415, that are designed to tackle various diseases and patient populations.

What sets Immuneering Corp apart is their disease-agnostic platform, which integrates bioinformatics and computational biology throughout the drug development process. This proprietary platform allows them to leverage human biological data in unique and unconventional ways, providing valuable insights and breakthrough discoveries. Immuneering Corp is at the forefront of innovation, striving to develop medicines with broad activity for large patient populations.

With their cutting-edge approach and dedication to transforming healthcare, they are making significant strides towards improving lives